ClinicalTrials.gg
RecruitingNCT07232810TMpEUpdated Dec 2, 2025

Prognostic Outcomes of Total Mesopancreas Excision for Pancreatic Head Cancer

An interventional study of Total Mesopancreas Excision (TMpE) in Pancreatic Head Cancer and Pancreatic Ductal Adenocarcinoma, sponsored by Minia University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-12-02.

Sponsored by Minia University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Pancreatic Neoplasms by Minia University — 11 open to participants now, 11 under way, 1 of them phase 3. Pancreatic Neoplasms · Minia University.

Planned enrollment
7th of 10
90 · median 100
Started
2025
with 8 others
No phase
6 of 13
6 open now
Primary completion
2027-12
later than 6 of 10 live
Registered
10th of 13
by date

Among the 13 studies in Pancreatic Neoplasms by Minia University, this one is the 7th largest by planned enrollment of the 10 interventional ones that give a count, is one of 9 that started in 2025, is one of 6 with no phase, reaches primary completion later than 6 of the 10 other live ones, and was the 10th registered.

Pancreatic Neoplasms

3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

11 of the 13 studies in Pancreatic Neoplasms by Minia University are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Pancreatic Neoplasms by Minia University, or all of them as a file.
02

Study summary

Pancreatic ductal adenocarcinoma (PDAC) has poor prognosis due to high recurrence rates after standard pancreaticoduodenectomy (PD). The concept of Total Mesopancreas Excision (TMpE), analogous to total mesorectal excision, aims to improve oncological outcomes by achieving higher R0 resection rates through the comprehensive removal of retroperitoneal connective tissue surrounding major peripancreatic vessels. This single arm prospective study will evaluate the prognostic outcomes, primarily Disease- Free Survival (DFS) at 24 months, of a standardized TMpE technique performed during pancreaticoduodenectomy for resectable pancreatic head cancer. Secondary objectives include assessing Overall Survival (OS), R0 resection rates, recurrence patterns, and perioperative outcomes in 90 consecutive patients.

Read the detailed description

Pancreatic duct adenocarcinoma (PDAC) is one of the most aggressive malignancies, with a 5-year overall survival rate of approximately 20-25% even after curative resection. Standard pancreaticoduodenectomy (PD, or Whipple procedure) often results in high rates of local recurrence (up to 40-50%) due to incomplete clearance of peripancreatic tissues, leading to R1 resections in 15-35% of cases. The concept of the "mesopancreas" was introduced by Gockel et al. in 2007 as an anatomical entity analogous to the mesorectum in rectal cancer surgery. Excision of the mesopancreas aims to achieve total en bloc removal of retroperitoneal tissues harboring lymphatic, neural, and vascular pathways for tumor spread, potentially improving R0 resection rates (to 80-90%), reducing local recurrence (to 15-20%), and enhancing survival. Existing retrospective and meta-analyses suggest that total mesopancreatic excision (TMpE) increases R0 rates and reduces locoregional recurrence while maintaining acceptable safety. However, prospective data are limited, and no large randomized trials exist. This study prospectively evaluates TMpE in resectable PDAC to assess its impact on local control and survival . Objectives

Primary Objectives:

  • To determine disease-free survival (DFS).

Secondary Objectives:

  • To assess the impact of TMpE on overall survival (OS).
  • To evaluate R0 resection rates and surgical morbidity.
  • To identify predictors of recurrence and survival through preoperative,intraoperative, and postoperative data.

DEFINITION OF MESOPANCREAS The mesopancreas is defined as the retropancreatic tissue located posterior to the pancreatic head, encompassing:

  • Anatomical boundaries: Inverted triangle with apex at the origins of celiac trunk (CT), hepatic artery, and superior mesenteric artery (SMA), and base at the posterior aspect of superior mesenteric vein(SMV) and portal vein(PV)
  • Tissue components: Adipose tissue, peripheral nerves and plexuses, vascular structures, lymphogenic structures, and locoregional lymph nodes
  • Alternative nomenclature: "Pancreatic head plexus", "retroportal lamina", "mesopancreatoduodenum"
  • Surgical margins: Includes retroperitoneal, uncinate, posterior, and portal vein groove margins This structure is the primary site for positive resection margins (R1) in PDAC and is implicated in locoregional spread.
  • Level of Dissection: The extent of mesopancreatic dissection can vary:
  • Level 1: Dissection close to the pancreatic capsule.
  • Level 2: Dissection along the superior mesenteric vein and portal vein.
  • Level 3 (Total Mesopancreas Excision): it involves dissecting along the entire length of the SMA and celiac axis, removing all lymphatic and neural tissue surrounding these vessels.
  • Mesopancreatic Excision (TMpE, Level 3):
  • After pancreatic neck transection, focus on posterior dissection.
  • Identify the mesopancreas as the retroperitoneal fibro-fatty tissue posterior to the pancreatic head.
  • Dissect along the right aspect of the SMA, exposing its origin from the aorta.
  • Extend dissection to the celiac trunk and right celiac ganglion, resecting nerve plexuses (e.g., plexus pancreaticus I and II).
  • Clear the aorto-caval groove laterally, including para-aortic lymph nodes (stations 16a2/b1 if involved).
  • En bloc removal of the mesopancreas: triangular resection bounded by portal vein /SMV (medial), SMA/celiac axis (posterior), and pancreatic head (anterior). Includes all lymphatic, neural, and fatty tissues up to the anterior aortic surface.
  • Ensure circumferential margin clearance: frozen section if needed for pancreatic neck, bile duct, and posterior margins.
  • Vascular skeletonization: clear adventitia of SMA and celiac trunk.
03

Conditions studied

  • Pancreatic Head Cancer
  • Pancreatic Ductal Adenocarcinoma

Keywords

  • Total Mesopancreas Excision
  • TMpE
  • Pancreaticoduodenectomy
  • Pancreatic Cancer
  • DFS
  • R0 Resection
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years.
  • Patients scheduled to undergo pancreaticoduodenectomy with planned mesopancreatic excision.
  • confirmed PDAC of the pancreatic head (via endoscopic ultrasound-guided ).
  • Resectable disease per National Comprehensive Cancer Network(NCCN) guidelines (no distant , no arterial involvement >180°, venous involvement reconstructable).
  • (ECOG) performance status 0-2.
  • Adequate organ function (e.g., \<1.5x (ULN), >50 mL/min).
  • .

Exclusion criteria

Exclusion Criteria:

  • Irresectable PDAC.
  • Distant .
  • Periampullary tumors other than pancreatic adenocarcinoma
  • Prior chemotherapy or radiotherapy (to isolate TMpE effect;may be amended for subgroups).
  • Active second .
  • Severe comorbidities precluding surgery (e.g., uncontrolled cardiac disease).
  • Pregnancy or lactation.
  • Patients who have received prior radiotherapy to the abdomen.
  • Patients unwilling or unable to provide .
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Total Mesopancreas Excision (TMpE)

    Patients with resectable or borderline resectable pancreatic head cancer undergoing pancreaticoduodenectomy with curative intent.

    Procedure: Total Mesopancreas Excision (TMpE)

Interventions

  • ProcedureTotal Mesopancreas Excision (TMpE)

    All patients undergo pancreaticoduodenectomy with total mesopancreatic excision (TMpE) and Adjuvant chemotherapy. -Meticulous dissection and en bloc removal of the fatty tissue and perineural lymphatic layer located between the head of the pancreas and the superior mesenteric vessels (superior mesenteric artery and portal vein) and the celiac axis, performed during pancreaticoduodenectomy.

    Also known as: TMpE

06

What researchers measure

Primary outcomes

  1. Disease-Free Survival (DFS)

    Time from surgery to first evidence of local recurrence, distant metastases, or death from any cause, whichever occurs first.

    Time frame: 24 months post-surgery

Secondary outcomes

  1. R0 Resection Rate

    Complete microscopic removal of the tumor with all surgical margins (including mesopancreatic margin) free of tumor cells. Assessed according to standardized protocols (e.g., College of American Pathologists guidelines). The status of all margins (proximal, distal, circumferential, and mesopancreatic) will be recorded.

    Time frame: Within 30 days post-surgery (Pathology report)

  2. Lymph Node Yield and Ratio

    To quantify the total number of lymph nodes harvested and the ratio of positive to total lymph nodes.

    Time frame: Within 30 days post-surgery (Pathology report)

  3. Completeness of Mesopancreas Excision

    Assessment through detailed pathological evaluation.

    Time frame: Within 30 days post-surgery (Pathology report)

  4. Overall Survival (OS)

    Time from surgery to death from any cause.

    Time frame: Up to 24 months post-surgery

  5. Prognostic Factors

    Identification of factors (preoperative, intraoperative,and pathological) associated with DFS and OS.

    Time frame: Up to 24 months post-surgery

  6. Recurrence-Free Survival (RFS)

    Time from the date of surgery to the date of first recurrence (local, regional, or distant).Calculated in months from the date of surgery. Recurrence will be confirmed by imaging (CT/MRI), biopsy, or clinical assessment. Patients without recurrence will be censored at the last follow-up date.

    Time frame: Up to 2 years post-surgery

  7. Local Disease Control

    Defined as tumor recurrence in the pancreatic bed, retroperitoneum, or regional nodes (via CT/MRI/ positron emission tomography (PET)-CT). Assessed by RECIST 1.1 criteria. Time-to-recurrence was calculated from surgery date to detection date.

    Time frame: Up to 2 years post-surgery (assessed at 3, 6, 12, 18 and 24 months).]

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Safi SA, Haeberle L, Fluegen G, Lehwald-Tywuschik N, Krieg A, Keitel V, Luedde T, Esposito I, Rehders A, Knoefel WT. Mesopancreatic excision for pancreatic ductal adenocarcinoma improves local disease control and survival. Pancreatology. 2021 Jun;21(4):787-795. doi: 10.1016/j.pan.2021.02.024. Epub 2021 Mar 17. PubMed 33775563 ↗
  • Xu J, Tian X, Chen Y, Ma Y, Liu C, Tian L, Wang J, Dong J, Cui D, Wang Y, Zhang W, Yang Y. Total mesopancreas excision for the treatment of pancreatic head cancer. J Cancer. 2017 Sep 30;8(17):3575-3584. doi: 10.7150/jca.21341. eCollection 2017. PubMed 29151943 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2027, 24 months after the start.

Of 405 non-industry interventional studies with no phase under Pancreatic Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 75. This study's planned 24 months is below that.

Counting every sponsor, half of 432 studies reached it within 44 months; a quarter within 26 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2025
First posted
Nov 18, 2025
StartActual
Dec 1, 2025
Primary completionEst.
Dec 1, 2027
CompletionEst.
Dec 20, 2027
Last update
Dec 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07232810
Lead sponsor
Minia University
Responsible party
Saleh Khairy Saleh MD (Lecturer, Minia University) — Principal investigator
First posted
Nov 18, 2025
Start date
Dec 1, 2025
Primary completion
Dec 1, 2027 (estimated)
Completion
Dec 20, 2027 (estimated)
Last update
Dec 2, 2025

Study contacts

Saleh K Saleh, MD
Contact
salehkhairy@mu.edu.eg
01201765401 ext. +2
Saleh K Saleh, MD
principal investigator · Minia University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion